Adarx operates in software/technology. The latest valuation stands at $827.8M. No public ticker exists for the company.
One company valuation: $827.8M.
BlackRockCCommodore CapitalCCormorant Asset ManagementHHBM Healthcare InvestmentsTTCG CrossoverIInvusMMarshall WaceRRedmile Group
T. Rowe Price
VenrockVVivo CapitalADARx Pharmaceuticals is a late clinical-stage biotechnology company developing next-generation RNA therapeutics, working across genetic, cardiometabolic and other disease areas through proprietary RNA delivery and silencing platforms. Its pipeline of wholly-owned clinical-stage programs spans complement-mediated, cardiovascular and thrombotic diseases, alongside preclinical discovery work in obesity and neurodegeneration, built on technology designed to produce targeted therapeutics for a broad range of conditions.
In May 2025, ADARx and AbbVie announced a collaboration and license-option agreement combining ADARx's siRNA discovery expertise with AbbVie's antibody and drug-conjugate engineering to develop next-generation siRNA therapies across neuroscience, immunology and oncology, with the partnership led by ADARx co-founder, president and chief executive officer Zhen Li.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Adarx.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Adarx availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Adarx included.
Lead investors for each round are in the funding timeline.
The closest software/technology peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Adarx is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
